About Standigm
Standigm is a leading healthcare AI company that leverages artificial intelligence for drug discovery and development. Founded in 2015, the company aims to revolutionize the traditional drug discovery lifecycle by applying its AI technologies across various stages, including target discovery, hit identification, hit-to-lead, and lead optimization. Standigm’s proprietary AI platforms, such as Standigm ASK™ for novel target identification and Standigm BEST™ for novel compound generation, are designed to accelerate the development of first-in-class and best-in-class drug candidates.
For physicians, Standigm’s approach means potentially faster and more efficient identification of novel therapeutic targets and the design of new chemical structures, which could lead to a more robust pipeline of innovative treatments. The company’s workflow AI, Standigm Magic™, integrates these platforms to streamline the process from target discovery to lead compound series, aiming to complete this phase in an average of seven months. Standigm also offers AI platform services, including QIP-ADMET for predicting Absorption, Distribution, Metabolism, Excretion, and Toxicity, SPICA for novelty assessment, STELLA for hit-to-lead optimization, and ASK-LLM for knowledge graph-to-text generation, to empower partners in accelerating their drug discovery processes.
Focus Areas
Business Intelligence
| Technology | AI operating system (Standigm AI), deep learning, machine learning, proprietary algorithms for drug discovery |
What Physicians Need to Know
For physicians, Standigm's AI-driven platforms offer the potential for faster identification of novel drug targets and the development of first-in-class compounds, potentially leading to new therapeutic options for challenging diseases like oncology and Parkinson's. Their drug repurposing efforts could also uncover new uses for existing medications, accelerating treatment availability. The explainability of their AI models means that the hypotheses generated are testable and can lead to actionable validation plans, which can be valuable for understanding the underlying biology and clinical implications of potential drug candidates.
Standigm offers AI SaaS & API solutions, including QIP-ADMET for ADMET prediction, SPICA for novelty assessment, STELLA for hit-to-lead optimization, and ASK-LLM for knowledge graph-to-text generation. They actively seek collaboration with pharmaceutical companies and universities for novel drug discovery and are looking to partner with Big Tech companies to expand their database and develop further technology. This suggests potential for integration of their AI platforms and data with external research and development pipelines.
Videos
News, demos, and interviews about Standigm.
Videos load interactively. If none appear, search YouTube for Standigm →
Frequently Asked Questions
Related Companies
Evaxion Biotech is a pioneering clinical-stage TechBio company that leverages its proprietary, clinically validated, and scalable AI platform, AI-Immunology™, to decode the human immune system. This platform is used to discover and develop novel immunotherapies for cancer, infectious diseases, and increasingly, autoimmune diseases. The company’s mission is to transform patients’ lives by providing inventive and […]
Mayo Clinic Platform is a strategic initiative of Mayo Clinic that aims to transform healthcare globally by leveraging data and technology. It focuses on redefining how care is provided, making personalized, predictive, and innovative care accessible to all. The platform supports innovation and collaboration around secure, de-identified clinical data to create, validate, and scale digital […]
Blaze.tech is an AI-powered, no-code platform that enables healthcare organizations to rapidly build and deploy custom, HIPAA-compliant web applications and internal tools without writing any code. This platform is designed to improve operations and productivity by allowing non-technical personnel, including physicians and administrative staff, to create tailored software solutions. These solutions can range from patient […]
